Real Progress in the Fight Against Cancer

| Newspaper | Reach: 545 | Sentiment: Positive

Sunday Star-Ledger - What risk factors related to specific cancers have you seen most frequently among both your older and younger patients? Dr. Steven K. Libutti: Risk factors including lifestyle choices and a family history of cancer are seen most frequently among both older and younger patients. At Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, genetic testing is available to further define one’s own risk of cancer as well as the risk to one’s relatives. Read More

Partial Breast Stereotactic Radiation May Lead to Less Toxicity in Breast Cancer Treatment

| Online Publication | Erin Hunter | Reach: 383,848 | Sentiment: Neutral

Pharmacy Times - David D'Ambrosio, MD, radiation oncologist at RWJBarnabas Health, joins Pharmacy Times to discuss CyberKnife, a new type of stereotactic body radiation that precisely targets tumors in stage 0 and stage 1 breast cancer patients. He is contributing author for a poster presented at the San Antonio Breast Cancer Symposium on December 6, 2022, which discussed the new radiation program
and its treatment potential. David D’Ambrosio, MD: Doing the standard-of-care for treatment of breast cancer with radiation therapy is typically somewhere in the neighborhood of 3 to 6 weeks of radiation every day, Monday through Friday. So, there has been—not recently but for many, many years—a movement to try to simplify this.

Read More

Middletown Boy Facing Leukemia Buoyed by Friends, Family and NJ Devils

| Online Publication | Carly Baldwin | Reach: 10,314,250 | Sentiment: Neutral

Share article: Facebook | Twitter | LinkedIn | Email

**Middletown Patch** - It was a surreal moment Martina Ferguson says she will never forget. It was an afternoon this past May and the Middletown mom was watching her son, 8-year-old RJ, and a friend play in the backyard when the call came in from the Rutgers Cancer Institute. "By that point, I had just had it. I was like, I cannot deal with this anymore. We are getting some answers," Martina Ferguson said. "I threw him in the car, and we just drove north up to Robert Wood Johnson (University Hospital)." RJ was admitted to the hospital for a full-body MRI and blood tests, plus a bone marrow biopsy. RJ can only go to school at Nut Swamp four days a week, and only in the mornings, because he is otherwise up at Rutgers Cancer Institute in New Brunswick receiving chemotherapy. Another thing to help take his mind off his diagnosis was a trip to see professional hockey. On Nov. 21 RJ joined the NJ Devils on the ice for their Hockey Fights Cancer Night, in collaboration with RWJBarnabas Health. Read More
Be the Change: The Importance of Making Cancer Prevention Programs Available

Broadcast | Reach: 22,859 | Sentiment: Positive

WCCO-MIN (CBS) - Minneapolis, MN - According to the National Cancer Institute, approximately 39.5% of men and women will be diagnosed with cancer at some point in their lifetimes. Madeline LoRe and Carol Trojan recently pledged a million dollars to the opening of the Madeline LoRe foundation infusion center in Jersey City as part of the medical center and partnered with Rutgers Cancer Institute of New Jersey. "We actually went out to dinner, with the CEO of the hospital and a couple of his staff. He mentioned that Rutgers Cancer Institute was going to have a footprint in Jersey City," said Madeline LoRe.

Read More

Also syndicated in:

WJZ-BAL (CBS) - Baltimore, MD, The CW Philly 57 - Philadelphia, PA, WBFS (MyNetworkTV) - Miami, FL, KCAL-LA - Los Angeles, CA, CW 50 - Detroit, MI, myTV38 - Boston, MA, KTXA - Dallas, TX, KBCW 44 Cable 12 - San Francisco, CA, WLNY - New York, NY, Pittsburgh's CW - Pittsburgh, PA and 2 More

Syndicated Reach: TM - 27,631

Then and Now: ‘Topping Off’ Celebrates the Future of Cancer Care

Online Publication | Reach: N/A | Sentiment: Positive

Share article:  

Facebook | Twitter | LinkedIn | Email
The Cancer History Project - Rutgers Cancer Institute of New Jersey, first called “The Cancer Institute of New Jersey,” started seeing patients in 1993 as the result of a P20 planning grant that was awarded in 1992. Some 20 years later in 2022, RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with the New Brunswick Development Corporation, hosted a topping off ceremony for the new Jack and Sheryl Morris Cancer Center in New Brunswick, the state’s first freestanding cancer hospital – a 12-story, 520,000 square-foot facility, which is set for completion in 2024. Read More

Navigating Seasonal Affective Disorder and Cancer This Winter

| Online Publication | Reach: 10,314,250 | Sentiment: Neutral

Share article:  

New Brunswick Patch - During the colder, darker days of winter, it is not uncommon for many people to feel more sluggish than usual. Nina Debrot, MSW, LSW, social worker at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, shares more about SAD and ways for cancer patients and caregivers to cope this season. SAD is marked by common depression symptoms. These symptoms can include changes in appetite and weight, increased fatigue, withdrawal from friends and family, problems sleeping, feeling sluggish, and a loss of interest in activities that can affect your productivity. Read More
Rutgers Archives: Joseph R. Bertino on Genomics and Cancer Risk

| Online Publication | Reach: 8,298 | Sentiment : Positive

The Cancer Letter - Rutgers Cancer Institute of New Jersey opened its doors in 1993 as the result of a P20 planning grant, and in 1997 became the first NCI-designated cancer center in New Jersey. Since then, Rutgers Cancer Institute has expanded its facilities, services, research and development. The panel was moderated by Joseph R. Bertino, who was interim director of Rutgers Cancer Institute of New Jersey at the time of this recording. Participants of the roundtable include Kimberly Ranieri of Rutgers Cancer Institute, David August of Rutgers Cancer Institute, Susan Brooks of Robert Wood Johnson Medical School, Judy Garber of Dana-Farber Cancer Institute, Paul Miller of University of Washington, Timothy Rebbeck of University of Pennsylvania School of Medicine, Deborah Toppmeyer of Rutgers Cancer Institute, and Xangpu Xu of Weill Cornell Medical College. “What we’re going to do in this session is place today’s scientific and ethics discussion into a clinical context,” Bertino said. “We have chosen to discuss a hypothetical case of a family in which breast cancer has been identified.” Read More

TDM1, Radiation Considered Safe for Patients With Early-Stage HER2-Positive Breast Cancer

Dec 09 | Online Publication | Erin Hunter | Reach: 383,848 | Sentiment : Positive

Pharmacy Times - Mridula George, MD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of
New Jersey and RWJBarnabas Health, presented a poster of the retrospective results of a study looking at the risks of cardiotoxicity with adjuvant therapy, trastuzumab emtansine, with adjuvant breast radiation for early-stage and HER2-positive metastatic breast cancer at the San Antonio Breast Cancer Symposium. Mridula George, MD: So trastuzumab emtansine is one of the drugs that's used for the treatment of early-stage and metastatic HER2-positive breast cancers. HER2-positive breast cancers comprise about 15% to 20% of all the breast cancers that are diagnosed in the US and worldwide.

---

**Second-Line Polatuzumab Vedotin Plus R-ICE in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Produces High ORR**

| Online Publication | Reach: 383,848 | Sentiment: Positive

Pharmacy Times - Pharmacy Times® interviewed Matthew J. Matasar, MD, MS, chief of blood disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, on his poster presentation titled “Polatuzumab Vedotin Combined with R-ICE. As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.”

Matthew J. Matasar: So, despite ongoing progress in the treatment of relapsed large cell lymphoma with the advent of CAR T and other treatments, platinum-based chemotherapy remains the standard of care for patients with late relapsing diffuse large B cell lymphoma. R-ICE is a standard chemo immunotherapy program combining rituximab with the platinum chemotherapy platform of ICE, ifosfamide, carboplatin, and etoposide.

Read More
Investigators Develop Model To Predict Overall Survival in Adults Diagnosed With Advanced Stage Hodgkin Lymphoma

Tufts Medicine Integrated Network - Investigators from Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center and leading cancer program along with Tufts Medical Center in Boston, developed and validated the Advanced-stage Hodgkin lymphoma International Prognostication Index. A-HIPI is a state-of-the-art clinical decision model to predict five-year progression-free and overall survival in adults with advanced-stage classic Hodgkin lymphoma using comprehensive individual patient data from international clinical trials and large prospective cancer registries.

An All-Encompassing Fight Against Cancer

New Jersey Business Magazine - As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, is at the forefront of cancer research, treatment, prevention and education. we recently broke ground on our northern hub for the
integrated oncology services offered by RWJBarnabas Health and Rutgers Cancer Institute on the campus of Cooperman Barnabas Medical Center in Livingston. Read More

2022 ASH Conference Report: Bispecifics for NHL Patients

| Online Publication | Matthew Matasar | Reach: 67,498 | Sentiment: Positive

Patient Power - Matthew Matasar, MD, Chief of Division of Blood Disorders, Rutgers Cancer Institute, in partnership with RWJBarnabas Health, "Antibodies are proteins that shape like a Y they bind with bacteria or cancer cells for using it as medicine." How long do these medicine when work? "we recognize that they are effective, we are very encouraging it." Read More

Also syndicated in:
OBR Oncology

Syndicated Reach: TM - N/A

Matasar Looks at Various Treatment Options in the DLBCL Setting for Transplant-Ineligible Patients
Targeted Oncology - During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, RWJBarnabas Health, Professor of Medicine Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy. The GO29365 trial [NCT02257567] led to the approval of polatuzumab vedotin-piIQ [Polivy] plus bendamustine [Bendeka] and rituximab [pola-BR]. This was a trial that actually had arms both for [follicular lymphoma (FL)] and for DLBCL. It had an expanded safety run-in where we gave patients BR along with obinutuzumab [Gazyva] instead of rituximab, because at that time we weren’t sure which of them was going to win
in parallel studies. And then, after the safety run-in, there was a randomized trial in DLBCL and a randomized trial in FL.

**IMV Inc. Reports Initial Data From the Ongoing Phase 2B VITALIZE Trial in Patients With R/R DLBCL**

Impact Financial News - A clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma who received at least three previous lines of treatment. "The initial clinical data from the VITALIZE trial are encouraging and the accelerating recruitment in this study reflects a growing interest for this therapeutic combination in DLBCL," said Dr. Matthew Matasar, Chief of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, and primary investigator of the VITALIZE trial.

**Imv Inc. Announces Initial Data From the Ongoing Phase 2B Vitalize Trial in Patients With R/R Dlbcl**

Share article:  |  Read More
Yahoo Finance - A clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced positive initial patient data from the Vitalize Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma who received at least three previous lines of treatment. "The initial clinical data from the Vitalize trial are encouraging and the accelerating recruitment in this study reflects a growing interest for this therapeutic combination in DLBCL," said Dr. Matthew Matasar, Chief of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, and primary investigator of the Vitalize trial. Read More

Also syndicated in:

Syndicated Reach: TM - 72,765,133

Updated Phase 2 Data Show Mosunetuzumab Monotherapy Provides Durable Efficacy, Manageable Safety Profile in Relapsed/Refractory Follicular Lymphoma

| Online Publication | Reach: 383,848 | Sentiment : Positive

Share article :  

Pharmacy Times - Pharmacy Times interviewed Matthew J. Matasar, MD, MS, chief of blood disorders, Rutgers Cancer Institute of New
Jersey and RWJBarnabas Health, on his poster presentation titled “Mosunetuzumab [Lunsumio; Genentech] Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study” at the 64th American Society of Hematology Annual Meeting and Exhibition in New Orleans, Louisiana. Read More

St. Luke’s To Partner With Rutgers Cancer Institute of New Jersey, Expanding Access to Clinical Trials for Cancer Care

| Online Publication | Jay Edwards | Reach: 10,304 | Sentiment: Positive

WRNJ radio - St. Luke’s University Health Network will expand its participation in clinical trials for cancer research though an innovative partnership with Rutgers Cancer Institute of New Jersey, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health. “We are excited to partner with St. Luke’s to bring our innovative clinical trials to their patients and the communities they serve,” said Steven K. Libutti, MD, Director of Rutgers Cancer Institute of New Jersey and Senior Vice President of Oncology Services, RWJBarnabas Health. “Cutting-edge cancer care from New Jersey’s only NCI-designated Comprehensive Cancer Center transcends state borders.” Read More

Clinical Trial: Retifanlimab and Pelareorep in Metastatic Triple-Negative Breast Cancer
**Cancer Therapy Advisor** - Patients will receive pelareorep intravenously over 60 minutes on days 1, 2, 15, and 16 of each 28-day cycle. They will receive retifanlimab intravenously over 60 minutes on day 3 of each cycle. Treatment will continue until disease progression or unacceptable toxicity. Principal Investigator: Mridula A. George, MD, of Rutgers Cancer Institute of New Jersey in New Brunswick.

Read More

---

**Debbie’s Dream Foundation Celebrates a Successful Year of Serving the Stomach Cancer Community Through the Generous Support of Its 2022 Industry Partners**

**Yahoo! Finance** - Debbie’s Dream Foundation: Curing Stomach Cancer celebrates a successful year of providing critical resources and support to the stomach cancer community. This year’s National Symposium series also featured partnerships with Rutgers Cancer Institute of New Jersey and the Miami Cancer Institute of Baptist Health South Florida. Sponsors for the 2022 National and International symposia include DDF’s National Title Sponsors Amgen, Bristol Meyers Squibb, and Daiichi Sankyo, Title Sponsor Taiho Oncology, National Platinum Sponsor Merck, National Gold Sponsor Astellas, and Gold Sponsor Lilly Oncology. Read More

Also syndicated in:
What’s the Connection Between HPV and Cervical Cancer?

| Reach: 5,000 | Sentiment: Neutral |

James K. Aikins, Jr., MD, FACOG, FACS, chief of Gynecologic Oncology at Rutgers Cancer Institute of New Jersey and associate professor of Obstetrics, Gynecology and Reproductive Sciences at Rutgers Robert Wood Johnson Medical School, answers questions about cervical cancer and HPV that you might be embarrassed to ask.

"Cervical cancer is almost always caused by HPV, which nearly every sexually active person will be exposed to in their lifetime. People with healthy immune systems are able to clear the virus within one to two years, but when high-risk strains infect specific cells of the cervix it can lead to abnormal cell growth and precancerous changes. Over time and with persistent infection, this can lead to cervical cancer."

said James K. Aikins. Read More

New St. Luke’s Partnership Expands Access to Clinical Trials for Cancer Care

| Online Publication | Reach: 15,942 | Sentiment: Positive |

Share article:  

| Share article:  |  |  |  |  |  |
St. Luke’s University Health Network will expand its participation in clinical trials for cancer research through an innovative partnership with Rutgers Cancer Institute of New Jersey, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health. Read More

Rutgers Cancer Institute of New Jersey: Rutgers Cancer Institute’s Year in Review – 2022

Targeted News Service - As the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, is committed to providing the most advanced, comprehensive, and compassionate world-class cancer care to adults and children, conducting groundbreaking research, providing innovative clinical trials, and above all continuing to work together to conquer cancer. The Commission on Cancer, a quality program of the American College of Surgeons, has granted Three-Year Accreditation to the cancer program at Robert Wood Johnson University Hospital, an RWJBarnabas Health Facility, in partnership with Rutgers Cancer Institute. Read More

What’s the Connection Between HPV and Cervical Cancer?

Reach: 911,919 | Sentiment: Neutral
Cervical cancer is one of the most preventable cancers, yet more than 14,000 women in the U.S. will be diagnosed with the disease this year, according to the American Cancer Society. James K. Aikins, Jr., MD, FACOG, FACS, chief of Gynecologic Oncology at Rutgers Cancer Institute of New Jersey and associate professor of Obstetrics, Gynecology and Reproductive Sciences at Rutgers Robert Wood Johnson Medical School, answers questions about cervical cancer and HPV that you might be embarrassed to ask. What’s the connection between HPV and cervical cancer? Read More

St. Luke’s To Partner With Rutgers Cancer Institute of New Jersey

New Jersey Business Magazine - St. Luke’s University Health Network will expand its participation in clinical trials for cancer research through an innovative partnership with Rutgers Cancer Institute of New Jersey, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health. “We are excited to partner with St. Luke’s to bring our innovative clinical trials to their patients and the communities they serve,” stated Steven K. Libutti, MD, director of Rutgers Cancer Institute of New Jersey and senior vice president of oncology services, RWJBarnabas Health. Read More

Also syndicated in:
Inside Warren and Local News Today
MCL: Event-Free Survival at 2 Years Bodes Well

In this era of efficacious treatments for mantle cell lymphoma, patients who survive 2 years sans disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population, a recent study showed. These findings clearly showed that in one cohort of patients with MCL treated in the recent past, those patients going 2 years without evidence of disease progression or events “have a great prognosis,” said Matthew Matasar, MD, MS, chief of blood disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. (Subscription Required) Read More

Cancer Nutritionist Offers Advice for New Year Health Goals

The New Year is a popular time to make commitments for healthy living. For many people, eating a healthier diet, exercising more and losing weight are always at the top of the list. “Approach the new year with the resolve to make longer term, healthy and sustainable changes that will promote and support cancer prevention,” says Kristin Waldron, RD, CSO, clinical dietitian at Rutgers Cancer Institute of New Jersey. At Rutgers Cancer Institute of New Jersey, the state’s
leading cancer program and only National Cancer Institute-Designated Comprehensive Cancer Center, together with RWJBarnabas Health, part of a patient’s care includes professional support from a clinical dietitian/nutritionist. Nutrition experts are available to comment on nutrition for cancer prevention. Read More

Also syndicated in: and

Syndicated Reach: TM - N/A

**St. Luke’s Partnering With Rutgers Cancer Institute**

| Online Publication | Stacy Wescoe | Reach: 7,282 | Sentiment : Positive

Lehigh Valley Business - St. Luke’s University Health Network of Bethlehem, said it will expand its participation in clinical trials for cancer research though a partnership with Rutgers Cancer Institute, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health. (Subscription Required) Read More

**Healthy Resolutions for the New Year**

| Online Publication | Sue Baldani | Reach: N/A | Sentiment : Neutral

Share article :  

Share article :
City Lifestyle - While many of our new year’s resolutions pertain to optimizing our health, we’re not always sure how to go about it. What tests should we be having, how often, and when? Here to help guide us is Anokhi Shah, MD, a physician with Cooperman Barnabas Medical Center and member of RWJBarnabas Health Medical Group who has an office in Livingston. Just because we feel fine doesn’t mean that we don’t need to be regularly checked out for a myriad of medical issues. Read More

“One Size Can’t Fit All”: Risk-Adapted Therapy in MCL

| Online Publication | Matthew Matasar | Reach: 13,661 | Sentiment: Neutral
Share article: facebook | twitter | linkedin | email

OBR Oncology - Matthew Matasar, MD, Chief of the Division of Blood Disorders at Rutgers Cancer Institute in New Brunswick, New Jersey, explains the concept of risk-adapted therapy for mantle cell lymphoma, in which patients receive treatment based on the presence or absence of various features of their disease. “My hope is that we’re going to get to a place with the ongoing discovery in this space where we don’t take that one-size-fits-all approach, where patients who have adverse biology are preferentially receiving appropriate targeted or novel therapies as opposed to committing them to a course of chemotherapy that we anticipate from the get-go will be suboptimal in its effectiveness,” he said. Read More
Targeting T Cell Checkpoints and Myeloid Suppressors Is an Effective Immunotherapy in Pancreas Cancer

RON DePINHO - Pancreatic cancer is one of the most lethal human cancers. The mainstay of treatment for metastatic PDAC is chemotherapy, which offers modest and transient benefit. While immune checkpoint therapy has transformed treatment for many advanced cancers, PDAC has been recalcitrant to ICT, including anti-PD1 and anti-CTLA4 and is considered refractory to immune therapy. Authors include Pat Gulhati, Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA; Ronald DePinho, Department of Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA. Pat Gulhati1 and Ronald DePinho. Read More

Hillsborough Senior Wellness Center Welcomes 2023 With Busy Schedule

TAPinto Hillsborough - Jan. 23, 11 a.m. – “Hereditary Cancers” with Community Cancer Control Specialist Ashley Purper, Rutgers Cancer Institute of New Jersey. Learn how and why cancer forms in cells, what methods are used to identify the risk for cancer, information about genetic testing and genetic risk assessment, as well as what hereditary and lifestyle risk factors can increase a person’s risk for developing cancer. Read More
Cooperman Barnabas Medical Center Earns National Accreditation From the Commission on Cancer of the American College of Surgeons

| Online Publication | Reach: 1,493,932 | Sentiment: Positive

TAPinto Livingston - The Commission on Cancer, a quality program of the American College of Surgeons has once again granted Three-Year Accreditation to the cancer program at Cooperman Barnabas Medical Center, Livingston, NJ, an RWJBarnabas Health facility, in partnership with Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center. “Earning this prestigious accreditation again is a testament to the unparalleled expertise and quality of care our cancer team at Cooperman Barnabas Medical Center offers our patients and community across the continuum of cancer care services,” says Richard L. Davis, the hospital’s President and CEO. Read More

Also syndicated in:
TAPinto Hillside

Syndicated Reach: TM - 1,493,932
**ROI-NJ** - The cancer program at Cooperman Barnabas Medical Center in Livingston was again granted a three-year accreditation from the Commission on Cancer, it was announced this week. To earn voluntary CoC accreditation, a cancer program must meet 34 CoC quality care standards, be evaluated every three years through a survey process and maintain levels of excellence in the delivery of comprehensive patient-centered care. Cooperman Barnabas Medical Center, an RWJBarnabas Health facility, works in partnership with Rutgers Cancer Institute of New Jersey. “Earning this prestigious accreditation again is a testament to the unparalleled expertise and quality of care our cancer team at Cooperman Barnabas Medical Center offers our patients and community across the continuum of cancer care services,” CBMC CEO Richard Davis said. Read More